SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (Nasdaq:NSTR) today reported operating results for the second quarter of 2007. Planned investments in the Company’s EVEREST pivotal trial for stroke motor recovery, other clinical trials, and the RenovaTM Cortical Stimulation System resulted in a net loss of $7.0 million for the quarter ended June 30, 2007. This compares to a net loss of $10.1 million for the quarter ended June 30, 2006. The Company also reported cash and investments of $94.3 million at June 30, 2007 compared to $105.3 million at December 31, 2006.
